Crinetics Pipeline

CRN01941

For the Treatment of Neuroendocrine Tumors (NETs)

CRN01941 is an oral nonpeptide sst2 biased agonist currently in preclinical development for the treatment of NETs, which arise from cells of the enteroendocrine system in the gastrointestinal tract, lung or, more rarely, the pancreas. These tumors are usually slow growing and often initially asymptomatic. Therefore, many patients are only diagnosed at a time of extensive metastatic disease. In approximately 10% of cases, these tumors are associated with excess secretion of serotonin resulting in carcinoid syndrome, which is characterized by severe diarrhea and flushing. Patients with well- and moderately-differentiated tumors and distant metastases have a five-year survival probability of 35%.

Most NETs overexpress sst2 receptors and injected depots of peptide somatostatin analogs have become the first-line standard of care.